Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
Why Provention Bio Stock Skyrocketed 256% This Week
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
This biopharma stock jumped over 250% on Monday: what happened?
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
PRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to Shareholders
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
Sanofi to buy Provention Bio in deal worth $2.9 billion
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)
Provention Bio Announces the Grant of Inducement Awards
Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
2 Beaten-Down Stocks That Might Be too Cheap to Ignore
Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US
Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)
Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data
Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch
Why Shares of Provention Bio Went Up 30.3% in November
Is This Biotech Stock a Buy Following a Landmark Approval?
Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes
TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?
2 Stocks Jumping in Thursday's Premarket Trading
Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
1 Green Flag and 1 Red Flag for Provention Bio
Provention Bio Announces Senior Leadership Addition
Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
2 Under-the-Radar Biotech Stocks to Buy in 2022
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2022 Results - Earnings Call Transcript
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
Provention Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
Provention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022